Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
"OFFICIAL PARTNER RESMI FIFA WORLD CUP 2018 RUSSIA!
Ayo segera bergabung bersama kami dan Dukung Negara Jagoan kamu hanya di BOLAVITA
Info Lebih Lanjut Bisa Hub CS kami :
wechat : bolavita
whatup : 6281377055002
BBM: BOLAVITA(NEW)"
"HOT PROMO DARI P0KERV1TA untuk para member kami :
* B0nus Referral 20% Seumur Hidup
* Bonus Hariaan Hingga 3juta
* Bonus Bulanan Hadiah Spesial untuk member yang bermain selama 1 bulan penuh
* Bonus Turn0ver 0,5%
* NO ROBOT & ADMIN
* 100% Fair Play Member Vs Member
* Proses Withdraw & Deposit Tercepat
* Customer Service yang baik dan ramah
Contact Us Person :
? LIVECHAT P`O`K`E`R`V`1`T`A
? WA: 082312256064
? BBM : D88B0154"
